Quote | Hemostemix Inc. (TSXVC:HEM:CC)
Last: | $0.35 |
---|---|
Change Percent: | 6.06% |
Open: | $0.335 |
Close: | $0.35 |
High: | $0.35 |
Low: | $0.335 |
Volume: | 165,164 |
Last Trade Date Time: | 05/06/2022 04:55:48 pm |
News | Hemostemix Inc. (TSXVC:HEM:CC)
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four h...
2024-06-03 13:23:23 ET In a press release this morning, %Hemostemix Inc. (TSXV: $HEM) (OTC: $HMTXF) announced it had signed a Letter of Intent ("LOI") with CytoImmune Therapeutics. The LOI will re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manu...
Message Board Posts | Hemostemix Inc. (TSXVC:HEM:CC)
Subject | By | Source | When |
---|---|---|---|
Hemostemix got the World Economic Forum's Technology Pioneer Award for their revolutionary autologou | 05/05/2023 9:42:21 AM | ||
Hemostemix ($HEM) is bringing hope to those with ischemic diseases with their new autologous cell th | 05/04/2023 1:49:20 PM | ||
Investors, take note! Biotech leader Hemostemix($HEM) is revolutionizing the treatment of ischemic d | 05/03/2023 3:12:48 PM | ||
Hemostemix ($HEM) is dedicated to developing cell therapy as well as expanding the range of availabl | 05/01/2023 2:21:07 PM | ||
Treatments for sickle cell disease are among the potential products that Hemostemix Inc. (TSXV: $HEM | 04/28/2023 7:14:03 AM |
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four h...
2024-06-03 13:23:23 ET In a press release this morning, %Hemostemix Inc. (TSXV: $HEM) (OTC: $HMTXF) announced it had signed a Letter of Intent ("LOI") with CytoImmune Therapeutics. The LOI will re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manu...
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art c...